BIG
SYRE icon

Brooklyn Investment Group’s Spyre Therapeutics SYRE Stock Holding History

Brooklyn Investment Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-520
Closed -$7.79K – 2453
2025
Q2 		$7.79K Buy
+520
New +$7.69K ﹤0.01% 2291
2025
Q1 		– Sell
-120
Closed -$2.79K – 2880
2024
Q4 		$2.79K Buy
+120
New +$3.52K ﹤0.01% 1369

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Brooklyn Investment Group's SYRE Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Spyre Therapeutics (SYRE) in Q3 2025, closing a stake of 520 shares — an estimated $7.79K sold.

Brooklyn Investment Group first reported a position in SYRE in Q4 2024 and held it in 2 quarters. The position peaked at $7.79K in Q2 2025. 137 funds tracked by Wall St. Rank hold SYRE as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Spyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 520 Spyre Therapeutics shares in Q3 2025, an estimated $7.79K.
  • Brooklyn Investment Group first reported a position in Spyre Therapeutics in Q4 2024 and held it in 2 quarters.
  • Brooklyn Investment Group's Spyre Therapeutics position peaked at $7.79K in Q2 2025.
  • 137 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.